medigraphic.com
ISSN 0188-9796 (Impreso)

2000, Número 3

<< Anterior Siguiente >>

Rev Endocrinol Nutr 2000; 8 (3)


Miomatosis uterina, un enfoque endocrinológico

Bañuelos ÁR

Idioma: Español
Referencias bibliográficas: 79
Paginas: 94-99
Archivo PDF: 170.34 Kb.


RESUMEN

La miomatosis uterina a pesar de ser la neoplasia pélvica más común en la mujer, es un tópico casi olvidado de la endocrinología. No siempre es sintomática, pero la tendencia actual de retrasar la maternidad hace que resalte la asociación de miomatosis uterina e infertilidad y complicaciones obstétricas. La mejor opción sigue siendo la manipulación hormonal con análogos agonistas y antagonistas de LH-RH cuando se es nulípara o no se tiene paridad satisfecha. El objetivo de este trabajo es revisar los factores etiológicos, así como las diversas modalidades de tratamiento.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. . Buttram VC, Reiter RC. Uterine leiomyomata: etiology, symtomatology, and management. Fertil Steril 1981; 36: 433-45.

  2. Cramer SF, Robertson AL, Zaits NP et al. Growth potential of human uterine leiomyomas: some in vitro observations and their implications. Obstet Gynecol 1985; 66: 36-41.

  3. Tamaya T, Fujimoto J, Okada H. Camparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium. Acta Obstet Gynecol Scand 1985; 64: 307-9.

  4. Santoro N, Brown JR, Adel T et al. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996; 81: 1495-1501.

  5. Benagiano G. Uterine fibroids: Literature review and summary of posters. Horm Res 1989; 32 Suppl 1: 120.

  6. Greenberg MD, Kazamel T. Medical and socioeconomic impact of uterine fibroids. In: Hutchins FL, Greenberg MD editors. Uterine fibroids. Obstetrics and Gynecology Clinics of North America 1995; 22: 625-36.

  7. Entman S. Miomatosis uterina y adenomiosis. Tratado de Ginecología de Novak 1996: 391-400.

  8. Murasse E, Siegelman ES, Outwater EK, Pérez-Jaffe LA, Tureck RW. Uterine leiomyomas: histopathologic features, MR imaging findings, differential diagnosis, and treatment. Radiographics 1999; 19: 1179-97.

  9. Richard A, Prayson RA, William R. Pathologic considerations of uterine smooth muscle tumors. In: Hutchins FL, Greenberg MD editors. Uterine fibroids. Obstetrics and Gynecology Clinics of North America 1995; 22: 637-57.

  10. Wallach EE, Kenneth Ku. Myomata uteri and infertility. In: Hutchins FL, Greenberg MD editors. Uterine fibroids. Obstetrics and Gynecology Clinics of North America 1995; 22: 791-9.

  11. Rein M, Friedman A, Stuart J et al. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist Leuprolide Acetate. Fertil Steril 1990; 53: 1018-23.

  12. Vu K, Greespan D, Wu T, Zacur H, Kurman R et al. Cellular proliferation, estrogen receptor, progesterone receptor and bcl-2 expression in GNRH agonist-treated uterine leiomyomas. Hum Pathol 1998; 29: 359-63.

  13. Wiznitzer A, Marbach M, Hazum E et al. Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem Biophys Res Commun 1988; 152: 1326-31.

  14. Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjoblom P, Norgen A et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 1998; 83: 4092-6.

  15. Dawood V, Med M, Sabin N. Growth factors and leiomyomas. Infertility and Reproductive Medicine Clinics of North America 1996: 5-18.

  16. Imai A, Ohno T, Lido K, Fusoya Y, Furui T et al. Gonadotropin-releasing hormone receptor in gynecologic tumors. Cancer 1994; 74: 2555-61.

  17. Chandrasekhor Y, Heinec J, Osvankpe C et al. Insuline-Like Grown Factor I and II binding in human myometrium and leiomyomas. Am J Obstet Gynecol 1992; 166: 4.

  18. Longo K, Sun Y, Gore A. Insulin-Like Growth Factor-I effects on gonadotropin-releasing hormone biosyntesis in GT1-7 Cells. Endocrinology 1998; 139: 1125-32.

  19. Vollenhoven B, Herington A, Healy D. Messenger ribonucleic acid expression of the Insuline-Like Growth Factors and their binding proteins in uterine fibroids and myometrium. J Clin Endocrinol Metab 1993; 76: 1106-10.

  20. Matsuo H, Kurachi O, Shimomura Y, Samoto T, Maruo T. Molecular bases for the actions of sex steroids in the regulation of proliferation and apoptosis of human uterine leiomyoma. Oncology 1999; 57 Suppl 2: 49-58.

  21. Breviller-Fouche M, Vocher-Lavenu M, Fournier T et al. Endothelin A receptors in human uterine leiomyomas. Obstet Gynecol 1997; 90: 727-30.

  22. Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy S. Mainteinance of increased Bcl-2 expression in uterine leiomyomas after GNRH agonist therapy. J Reprod Med 1999; 44: 487-92.

  23. Yoshida M, Ohtsuru A, Samejima T, Okazaki M, Fujishita A, Ito M et al. Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas. Endocr J 1999; 46: 81-90.

  24. Kim JG, Kim MH, Kim IS, Moon SY, Kang SB, Lee HP et al. Decreased expression of mac25 mRNA in uterine leiomyomata compared with adjacent myometrium. Am J Reprod Immunol 2000; 43: 53-7.

  25. Sornberger KS, Weremowicz S, Williams AJ, Quade BJ, Ligon AH, Pedeutour F et al. Expression of HMGY in three uterine leiomyomata with complex rearrangements of chromosome 6. Cancer Genet Cytogenet 1999; 114: 9-16.

  26. Gattas GJ, Quade BJ, Nowak RA, Morton CC. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer 1999; 25: 316-22.

  27. Chiaffarino F, Parazzini F, La Vecchia C, Chatenoud L, Di Cintio E, Marsico S. Diet and uterine myomas. Obstet Gynecol 1999; 94: 395-8.

  28. Sato F, Nishi M, Kudo R, Miyake H. Body fat distribution and uterine leiomyomas. J Epidemiol 1998; 8: 176-80.

  29. Matsuno Y, Yamashita Y, Takahashi M, Katabuchi H, Okamura H, Kitano Y et al. Predicting the effect of gonadotropin-releasing hormone (GnRH) analogue treatment on uterine leiomyomas based on MR imaging. Acta Radiol 1999; 40: 656-62.

  30. Excoustos C, Rosati P. Ultrasound diagnosis of uterine myomas and complications in pregnancy. Obstet Gynecol 1993; 82: 97-101.

  31. Sullivan, Guzick D. The natural history of uterine myomas. Infertility and Reproductive Medicine. Clinics of North America 1996; 7: 1-4.

  32. Vergomi P, Ghidini A, Stroblet N et al. Do uterine leiomyomas influence pregnancy outcome? Am J Perinat 1994; 11: 356-8.

  33. Coronado GD, Marshall LM, Schwartz SM. Complications in pregnancy, labor and delivery with uterine leiomyomas: a population-based study. Obstet Gynecol 2000; 95: 764-9.

  34. Bulletti C, De Ziegler D, Polli V, Flamigni C. The role of leiomyomas in infertility. J Am Assoc Gynecol Laparosc 1999; 6: 441-5.

  35. Nazhat C, Nezhat F, Silfens et al. Laparoscopic myomectomy. Int J Fertil 1991; 36: 275-80.

  36. Dubuisson JB, Fauconnier A, Chapron C, Kreiker G, Norgaard C. Reproductive outcome after laparoscopic myomectomy in infertil women. J Reprod Med 2000; 45: 23-30

  37. Bernard G, Darai E, Poncelet C, Benifia JL, Madalenat P. Fertility after hysteroscopic myomectomy: effect of intramural myomas associated. Eur J Obstet Gynecol Reprod Biol 2000; 88: 85-90.

  38. Li TC, Mortimer R, Cooke ID. Myomectomy: a retrospective study to examine reproductive performance before and after surgery. Hum Reprod 1999; 14: 1735-40.

  39. Bernard G, Darai E, Poncelet C, Benifia JL, Madelenat P. Fertility after hysteroscopic myomectomy: effect of intramural myomas associated. Eur J Obstet Gynecol Reprod Biol 2000; 88: 85-90.

  40. Hutchins FL. Uterine fibroids. Diagnosis and indications for treatment. In Hutchins FL, Greenberg MD editors. Uterine fibroids. Obstetrics and Gynecology Clinics of North America 1995; 22: 659-65.

  41. Ramos AM, Arredondo MM, Martínez A et al. Leiomiomatosis uterina. Informe de 77 casos. Ginecol Obstet Mex 1990; 68: 138-41.

  42. Douglas D, Bradham PH, Thomas G, Stovall, Chis D, Thompson BS. Use of GNRH agonist before hysterectomy: a cost simulation. Obstet Gynecol 1995; 85: 401-6.

  43. Ferrari MM, Berianda N, Mezzopane R, Ragusa G, Cavallo M, Pardi G. Identifying the indications for laparoscopically assisted vaginal hysterectomy: a retrospective, randomized comparision with abdominal hysterectomy in patients with symptomatic uterine fibroids. BJOG 2000; 107: 620-5.

  44. Pelage JP, Le Dref O, Soyer P, Kardache M, Dahan H, Abitbol M et al. Fibroid-related menorrhagia: treatment with superselective embolization of the uterine arteries and midterm follow-up. Radiology 2000; 215: 428-31.

  45. Goldfarb HA. Laparoscopic coagulation of myoma (myolisis). In: Hutchins FL, Greenberg MD editors. Uterine fibroids. Obstetrics and Gynecology Clinics of North America 1995; 22: 807-19.

  46. Law P, Gedroye WM, Regan L. Magnetic-resonance-guided percutaneous laser ablation of uterine fibroids. Lancet 1999; 354: 2049-50.

  47. Filicori M, Hall DA, Loughlin JS et al. A conservative approach to the management of uterine leiomyomata: pituitary desensitization by a luteinizing hormone-releasing hormone analogue. Am J Obstet Gynecol 1983; 147: 726-7.

  48. Vercellini P, Maddalena S, Giorgi O et al. Abdominal myomectomy for infertility: a comprehensive review. Hum Reprod 1998; 13: 873-79.

  49. Herrera T, Guerra Garza A, Reyes H et al. Agonistas de GNRH en Ginecología I. Ginecol Obstet Mex 1992; 60: 146-51.

  50. Dubuisson JB, Fauconnier A, Chapron Ch et al. Second look after laparoscopic myomectomy. Hum Reprod 1998; 13: 2102-6.

  51. Neves-e-Castro M, Correia MF. Use of luteinizing hormone-releasing hormone analogs in non-neoplasic gynecologic conditions. Seminars in reproductive endocrinology 1987; 5: 411-19.

  52. Friedman A, Lobel S, Rein M, Barbieri R. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonist: the estrogen threshold hypothesis. Am J Obstet Gynecol 1990; 163: 1114-9.

  53. West CP, Lumsden MA, Baird DT. Goserelin (Zoladex) in the treatment of fibroids. Br J Obstet Gynecol 1992; 99: 27-30.

  54. Rivlin M, Rameshkumar B, Wayne Hess L, Hess D, Meeks G. Leuprolide acetate depot for the treatment of uterine leiomyomas. Changes in bone density, uterine volume and uterine vascular resistive index. J Reprod Med 1994; 39: 663-6.

  55. Friedman A, Doly M, Juneau-Norcros M, Rein M. Predictors of uterine volume reduction in women with myomas treated wiht a gonadotropin releasing-hormone agonist. Fertil Steril 1992; 58: 413-5.

  56. Zullo F, Pellicano M, De Stefano R et al. A prospective randomized study to evaluate leuprolide acetate treatment before laparoscopic myomectomy: efficacy and ultrasonographic predictors. Am J Obstet Gynecol 1998; 178: 108-12.

  57. Vavalá V, Lanzone A, Monaco A et al. Postoperative GNRH analog treatment for the prevention of recurrences of uterine myomas after myomectomy. A pilot study. Gynecol Obstet Invest 1997; 43: 251-4.

  58. Fedele L, Vercellini P, Bianchi S et al. Treatment with GNRH agonist before myomectomy and the risk of the short-term myoma recurrence. Br J Obstet Gynecol 1990; 1997: 393-6.

  59. Friedman A, Daly M, Juneau-Norcros M et al. A Prospective randomized trial of gonadotropin-releasing hormona agonist plus estrogen progestin or progestin “add-back” regimens for women with leiomyomata uteri. J Clin Endocrinol 1993; 76: 1439-45.

  60. Sherwin B, Tulandi T. “Add-back” estrogen reverses cognitive deficits induced by gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 1996; 81: 2545-9.

  61. Friedman A. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study. Fertil Steril 1989; 51: 526-8.

  62. Palomba S, Affinito P, Tommaselli GA, Nappi C . A clinical trial of the effects of Tibolane administered with gonatropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 1998; 70: 111-8.

  63. González-Bárcena D, Kastin AJ, Coy DH et al. Supression of gonadotropin release in man by an inhibitory analogue of luteinizing hormone-releasing hormone. Lancet 1977;2:997-8.

  64. Lumsden MA, West CP, Baird. Goserdin. Theraphy before surgery for uterina fibroids. Lancet 1987; 1: 36-7.

  65. Kettel LM, Yen SC. Terminology for GNRH antagonists. Fertil Steril 1994; 61: 995.

  66. Pinski J, Lamharzi N, Halpos G et al. Chronic administration of the luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix decreases gonadotrope responsiveness and pituitary LH-RH receptor messenger ribonucleic acid levels in rats. Endocrinology 1996; 137: 3430-6.

  67. González-Bárcena D, Vadillo-Buenfil M, Gracia-Procel E et al. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analogue of luteinizing hormone releasing hormone, Cetrorelix (SB-75). Eur J Endocrinol 1994; 131: 286-92.

  68. González-Bárcena D, Vadillo M, Gómez O et al. Responses to the antagonistic analogue of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hiperplasia and prostate cancer. Prostate 1994; 24: 84-92.

  69. González-Bárcena D, Vadillo M, Cortez A et al. Luteinizing hormone-releasing hormone antagonist Cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 1995; 45: 275-81.

  70. González-Bárcena D, Bañuelos R, Perez E, Cardenas C, Comaru-Schally AM, Schally AV et al. Treatment of Uterine Leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 1997; 12: 2028-35.

  71. Felberbeum R, Gemer U, Ludwing M, Riethmuller-Winzen H, Heise S, Buttge I et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod 1998; 13: 1660-8.

  72. Vercellini P, Zaina B, Yaylayan L, Pisacreta A, De Giorgi O, Crosignani PG. Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility. Obstet Gynecol 1999; 94: 341-7.

  73. Tulandi T, al-Took S. Endoscopic myomectomy. Laparoscopy and hysteroscopy. Obstet Gynecol Clin North Am 1999; 26: 135-48.

  74. Davies A, Hart R, Magos AL. The excision of uterine fibroids by vaginal myomectomy: a prospective study. Fertil Steril 1999; 71: 961-4.

  75. Dubuisson JB, Fauconnier A, Chapron Ch et al. Second look after laparoscopic myomectomy. Hum Reprod 1998; 13: 2102-6.

  76. Golan D, Aharoni A, Gonen R et al. Early spontaneous rupture of the post myomectomy gravid uterus. Int J Gynecol Obstet 1990; 31: 167-70.

  77. Davis KM, Schalaff WD. Medical management of uterine fibromyomata. In: Hutchins FL, Greenberg MD editors. Uterine fibroids. Obstetrics and Gynecology Clinics of North America 1995; 22: 727-38.

  78. Murphy AA, Kettel LM, Morales AJ et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993; 76: 513-7.

  79. De Leo V, la Marca A, Morgante G. Short-term treatment of uterine fibromyomas with Danazol. Gynecol Obstet Invest 1999; 47: 258-62.




2020     |     www.medigraphic.com